{
    "address": "Adelgatan 21",
    "city": "Malmo",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W2R52N108",
    "description": "Cyxone AB is a clinical stage biotech company, which engages in the development of immunomodulation drugs for the treatment of autoimmune diseases. The company is headquartered in Malmo, Skane and currently employs 6 full-time employees. The company went IPO on 2016-06-07. The firm develops cyclotide drugs for autoimmune and other diseases. The firm's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. The product T20K, through a pre-clinical program required for clinical studies in multiple sclerosis. The firm's cyclotides technology can be modified, while keeping the core cyclotide drug structure, to introduce a variety of pharmaceutical properties for selected diseases. The firm has acquired the cyclotide patent rights developed by the Medical University of Vienna and the University Medical Center of Freiburg.",
    "employeeTotal": "6.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2016-06-07",
    "isin": "SE0007815428",
    "logo": "",
    "marketCapitalization": 280.4974,
    "naics": "Pharmaceutical and Medicine Manufacturing",
    "naicsNationalIndustry": "Pharmaceutical Preparation Manufacturing",
    "naicsSector": "Manufacturing",
    "naicsSubsector": "Chemical Manufacturing",
    "name": "Cyxone AB",
    "phone": "46708882172.0",
    "sedol": "BD57CN3",
    "shareOutstanding": 58.0634,
    "state": "SKANE",
    "ticker": "CYXO.ST",
    "weburl": "http://cyxone.com/"
}